London, UK — 25 March 2025 — GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Blujepa (gepotidacin) for the treatment of female adults (≥40 kg) and paediatric patients (≥12 years, ≥40 kg)…Original Article
FDA Approves Blujepa (gepotidacin) for the Treatment of Uncomplicated Urinary Tract Infections
